Details:

Alternative Title:
PLoS One
Publisher's site:
http://dx.doi.org/10.1371/journal.pone.0036525
Personal Author:
Yang, Kun ; Mooney, Colin ; Spahlinger, Greg ; Schuetze, Scott ; Arias-Pulido, Hugo ; ... More +
Yang, Kun ; Mooney, Colin ; Spahlinger, Greg ; Schuetze, Scott ; Arias-Pulido, Hugo ; Verschraegen, Claire ; Gimotty, Phyllis ; Buckanovich, Ronald J. Less -
Description:
Background

The Death Receptor 6 (DR6) protein is elevated in the serum of ovarian cancer patients. We tested DR6 serum protein levels as a diagnostic/predictive biomarker in several epithelial tumors and sarcomas.

Methods

DR6 gene expression profiles were screened in publically available arrays of solid tumors. A quantitative immunofluorescent western blot analysis was developed to test the serum of healthy controls and patients with sarcoma, uterine carcinosarcoma, bladder, liver, and pancreatic carcinomas. Change in DR6 serum levels was used to assay the ability of DR6 to predict the response to therapy of sarcoma patients.

Results

DR6 mRNA is highly expressed in all tumor types assayed. Western blot analysis of serum DR6 protein demonstrated high reproducibility (r = 0.97). Compared to healthy donor controls, DR6 serum levels were not elevated in patients with uterine carcinosarcoma, bladder, liver, or pancreatic cancers. Serum DR6 protein levels from adult sarcoma patients were significantly elevated (p<0.001). This was most evident for patients with synovial sarcoma. Change in serum DR6 levels during therapy correlated with clinical benefit from therapy (sensitivity 75%, and positive predictive value 87%).

Conclusion

DR6 may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.

Impact

Diagnosis of sarcoma can be difficult and can lead to improper management of these cancers. DR6 serum protein may be a tool to aid in the diagnosis of some sarcomatous tumors to improve treatment planning. For patients with advanced disease, rising DR6 levels predict non-response to therapy and may expedite therapeutic decision making and reduce reliance on radiologic imaging.


Subject:
[+]
Biology
Blotting, Western
Female
Humans
Liver Neoplasms
Medicine
Ovarian Neoplasms
Pancreatic Neoplasms
Predictive Value Of Tests
Receptors, Tumor Necrosis Factor
Research Article
Sarcoma
Tumor Markers, Biological
Uterine Neoplasms

Source:
PLoS One. 2012; 7(5).
Pubmed ID:
22567163
Pubmed Central ID:
PMC3342254
Document Type:
Journal Article
Funding:
DP2 00440377/DP/NCCDPHP CDC HHS/United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:fe1f5b0f9ac21dadbeb2a2579409d83269bcd230a7c5fc7aabaddd097798546d
File Type:

Supporting Files

• 	pone.0036525.g004.jpg	jpeg
  	pone.0036525.nxml	txt
  	pone.0036525.t001.gif	gif
  	pone.0036525.t001.jpg	jpeg
  	pone.0036525.t002.gif	gif
  	pone.0036525.t002.jpg	jpeg
  	license.txt	txt
  	pone.0036525.g001.gif	gif
  	pone.0036525.g001.jpg	jpeg
  	pone.0036525.g002.gif	gif
  	pone.0036525.g002.jpg	jpeg
  	pone.0036525.g003.gif	gif
  	pone.0036525.g003.jpg	jpeg
  	pone.0036525.g004.gif	gif

More +